GPRC5B

GPRC5B Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
His Tag & Flag Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
GPB-H52D7	Human	HEK293	Human GPRC5B Protein, Flag,His Tag (Detergent)				Ajouter au panier

Quantité totale1

GPRC5BContexte de la molécule

This gene encodes a member of the type 3 G protein-coupled receptor family. Members of this superfamily are characterized by a signature 7-transmembrane domain motif. The encoded protein may modulate insulin secretion and increased protein expression is associated with type 2 diabetes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2015]

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Atacicept	TACI-Ig	Phase 3 Clinical	Zymogenetics Inc	Glomerulonephritis, IGA; Kidney Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Urinary Bladder Diseases; Lupus Erythematosus, Systemic	Details
Zigakibart	BION-1301	Phase 3 Clinical	Aduro Biotech Inc	Glomerulonephritis, IGA; Proteinuria; Multiple Myeloma	Details
Povetacicept	ALPN-303; ALPN 30x	Phase 3 Clinical		Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis	Details
Sibeprenlimab	VIS-649	Phase 3 Clinical	Visterra Inc	Glomerulonephritis, IGA; Glomerulonephritis	Details
IM-21	IM21; IM-21	Phase 1 Clinical	Beijing Yimiao Medical Technology Co Ltd	Multiple Myeloma	Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)		Phase 1 Clinical	Eugia Pharma Specialities Ltd, Actavis Inc	Multiple Myeloma	Details
anti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital）		Phase 1 Clinical	Massachusetts General Hospital	Multiple Myeloma	Details
AUR-200	AUR-200; AUR200	Phase 1 Clinical	Thunderbolt Pharma Inc	Autoimmune Diseases	Details
RO-7297089	RO-7297089; AFM-26; RG-6296	Phase 1 Clinical	Genentech Inc	Multiple Myeloma	Details
APRIL CAR-T Cell therapy (Yake Biotechnology)		Phase 1 Clinical	Shanghai YaKe Biotechnology Co Ltd	Multiple Myeloma	Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)		Clinical	Huazhong University Of Science And Technology	Multiple Myeloma	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Telitacicept	RCT-18; RC-18; RCT18; RC18	Approved	RemeGen Co Ltd		Mainland China	Lupus Erythematosus, Systemic	RemeGen Co Ltd	2021-03-09	Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Nephrosis; Immunoglobulin G4-Related Disease; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic	Details